Rapid development of a perfusion process with high productivity by Xu, Sen et al.
Engineering Conferences International
ECI Digital Archives
Cell Culture Engineering XV Proceedings
Spring 5-11-2016
Rapid development of a perfusion process with
high productivity
Sen Xu
Merck, sen.xu@merck.com
Linda Hoshan
Meck
Balrina Gupta
Merck
Hao Chen
Merck
Follow this and additional works at: http://dc.engconfintl.org/cellculture_xv
Part of the Biomedical Engineering and Bioengineering Commons
This Abstract is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Cell Culture
Engineering XV by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.
Recommended Citation
Sen Xu, Linda Hoshan, Balrina Gupta, and Hao Chen, "Rapid development of a perfusion process with high productivity" in "Cell
Culture Engineering XV", Robert Kiss, Genentech Sarah Harcum, Clemson University Jeff Chalmers, Ohio State University Eds, ECI
Symposium Series, (2016). http://dc.engconfintl.org/cellculture_xv/152
 LATE STAGE DEVELOPMENT OF A FED-BATCH PROCESS: CHANGING EVERYTHING BUT PRODUCT 
QUALITY 
Sen Xu, Process Development & Engineering, BioProcess Development, Merck Research Laboratories, 
2000 Galloping Hill Road, Kenilworth, NJ 07033  
sen.xu@merck.com  
Linda Hoshan, Process Development & Engineering, BioProcess Development, Merck Research Laboratories, 
2000 Galloping Hill Road, Kenilworth, NJ 07033  
Balrina Gupta, Process Development & Engineering, BioProcess Development, Merck Research Laboratories, 
2000 Galloping Hill Road, Kenilworth, NJ 07033  
Hao Chen, Process Development & Engineering, BioProcess Development, Merck Research Laboratories, 
2000 Galloping Hill Road, Kenilworth, NJ 07033  
 
 
 
Key Words:      Feeding strategy, Productivity, Product Quality, Scale-Up 
 
 
Continuous process improvement is required during a biologics process life cycle to increase process yield and 
reduce cost. In this poster, we will present a case study in late stage process development where everything 
was changed but the product quality. The following major changes were made when developing the new 
process: 
 Production cell line – subclone of the original clone used. 
 Media – from hydrolysate-containing feeds to fully chemically-defined feeds. 
 Feeding strategy – from fixed volume/fixed schedule feeding to daily on-demand feeding. 
Media components were optimized through spent media analysis and mechanistic understanding to 
accommodate the new feeding strategy. High-throughput bioreactor systems (ambr15TM and ambr250TM) were 
used for rapid screening of experimental conditions, and the results were confirmed in 3 L bioreactors. As a 
result of the development effort, a 100% increase in peak cell density to 20-25e6 cells/mL, a 40% decrease in 
peak lactate level, and a 140% increase in antibody titer were achieved in the new process. Titer increase was 
attributed to the improved oxidative metabolism and significant increase in cumulative cell density. In the new 
process, final culture viability was still maintained at >90%, benefiting filtration primary recovery. The process 
was scaled-up to a 200 L SUB without losing productivity.  
We show that product quality, especially N-linked glycosylation and charge variants, could be modulated by 
adjusting specific medium components and feeding strategy. The antibody quality attributes resulting from the 
new process are comparable with (or better than) those from the old process.  
 
 
 
